Last reviewed · How we verify

Ketorolac, intramuscular

The University of Texas Medical Branch, Galveston · FDA-approved active Small molecule

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Moderate to severe acute pain (short-term use, typically ≤5 days), Postoperative pain.

At a glance

Generic nameKetorolac, intramuscular
Also known asToradol
SponsorThe University of Texas Medical Branch, Galveston
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Ketorolac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, ketorolac provides rapid analgesic and anti-inflammatory effects. The intramuscular formulation allows for quick onset of action, making it suitable for acute moderate to severe pain management in hospital and clinical settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: